hydroxychloroquine has been researched along with Drug Withdrawal Symptoms in 4 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The primary outcome was time to a major flare of SLE which resulted in either the institution of or an increase in the current dosage of prednisone of 10 mg/day or more, or institution of therapy with immunosuppressive agents." | 2.69 | A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. ( Choquette, D; Cividino, A; Danoff, D; Esdaile, JM; Joseph, L; Osterland, CK; Senécal, JL; Smith, CD; Tsakonas, E; Yeadon, C, 1998) |
| "Patients with quiescent systemic lupus erythematosus who are taking hydroxychloroquine are less likely to have a clinical flare-up if they are maintained on the drug." | 2.67 | A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. ( , 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ebrahimiadib, N | 1 |
| Riazi-Esfahani, H | 1 |
| Heidari, M | 1 |
| Mahmoudi, A | 1 |
| Zenone, T | 1 |
| Knefati, Y | 1 |
| Tsakonas, E | 1 |
| Joseph, L | 1 |
| Esdaile, JM | 1 |
| Choquette, D | 1 |
| Senécal, JL | 1 |
| Cividino, A | 1 |
| Danoff, D | 1 |
| Osterland, CK | 1 |
| Yeadon, C | 1 |
| Smith, CD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431] | Phase 4 | 93 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| Hydroxychloroquine Exposure in Systemic Lupus Erythematosus (SLE)[NCT03802188] | 3,700 participants (Anticipated) | Observational | 2018-05-09 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Inactive SLE With Standard Dose of HCQ | 991.6 |
| Inactive SLE With Reduced Dose of HCQ | 569.0 |
Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| SLE/Cutaneous Lupus With Thalidomide | 415.1 |
2 trials available for hydroxychloroquine and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
Topics: Adult; Antimalarials; Azathioprine; Cyclophosphamide; Female; Follow-Up Studies; Humans; Hydroxychlo | 1998 |
A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
Topics: Adult; Antimalarials; Azathioprine; Cyclophosphamide; Female; Follow-Up Studies; Humans; Hydroxychlo | 1998 |
A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
Topics: Adult; Antimalarials; Azathioprine; Cyclophosphamide; Female; Follow-Up Studies; Humans; Hydroxychlo | 1998 |
A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
Topics: Adult; Antimalarials; Azathioprine; Cyclophosphamide; Female; Follow-Up Studies; Humans; Hydroxychlo | 1998 |
A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus.
Topics: Adult; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Lupus Ery | 1991 |
2 other studies available for hydroxychloroquine and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Ocular flare-up in patients with systemic lupus erythematosus following discontinuation of hydroxychloroquine.
Topics: Aged; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Middle Aged; Retinal | 2020 |
[Renal infarction in systemic lupus with antiphospholipid syndrome: role of hydroxychloroquine withdrawal? Comment on the article by Szymezak et al].
Topics: Adult; Antibodies, Anticardiolipin; Antibodies, Antinuclear; Anticoagulants; Antiphospholipid Syndro | 2011 |